摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-tert-butyl 5-fluoro-2,4-dioxone-3,4-dihydropyrimidine-1(2H)-carboxylate | 402849-04-1

中文名称
——
中文别名
——
英文名称
1-tert-butyl 5-fluoro-2,4-dioxone-3,4-dihydropyrimidine-1(2H)-carboxylate
英文别名
tert-butyl 5-fluoro-2,4-dioxo-pyrimidine-1-carboxylate;1-(t-butoxycarbonyl)-5-fluorouracil;1-BOC-5-fluorouracil;N1-Boc-5-fluorouracil;tert-butyl 5-fluoro-2,4-dioxopyrimidine-1-carboxylate
1-tert-butyl 5-fluoro-2,4-dioxone-3,4-dihydropyrimidine-1(2H)-carboxylate化学式
CAS
402849-04-1
化学式
C9H11FN2O4
mdl
——
分子量
230.196
InChiKey
MYYPVGBRGVYDCX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.35±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.3
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    75.7
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    1-tert-butyl 5-fluoro-2,4-dioxone-3,4-dihydropyrimidine-1(2H)-carboxylate 在 sodium hydride 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 生成 5-fluoro-3-[3-[4-[4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl]propyl]-1H-pyrimidine-2,4-dione
    参考文献:
    名称:
    Synthesis, pharmacology and pharmacokinetics of 3-(4-Aryl-piperazin-1-ylalkyl)-uracils as uroselective α1A-antagonists
    摘要:
    Predominance in the urethra and prostate of the alpha(1A)-adrenoceptor subtype, which is believed to be the receptor mediating noradrenaline induced smooth muscle contraction in these tissues, led to the preparation of alpha(1A)-selective antagonists to be tested as uroselective compounds for the treatment of benign prostatic hyperplasia. Thus, a number of selective alpha(1A)-adrenoceptor antagonists were synthesized and assayed in vitro for potency and selectivity. Dog pharmacokinetic parameters of 12 (RO700004) and its metabolite 40 (RO1104253) were established. The relative selectivity of intravenously administered 12, 40 and standard prazosin to inhibit hypogastric nerve stimulation-induced increases in intraurethral prostatic pressure versus phenylephrine-induced increases in diastolic blood pressure in anesthetized dogs was 76, 71 and 0.6, respectively. (C) 2003 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0960-894x(03)00305-6
  • 作为产物:
    描述:
    5-氟脲嘧啶二碳酸二叔丁酯4-二甲氨基吡啶 作用下, 以 乙腈 为溶剂, 反应 3.0h, 以92%的产率得到1-tert-butyl 5-fluoro-2,4-dioxone-3,4-dihydropyrimidine-1(2H)-carboxylate
    参考文献:
    名称:
    新型新型的酸性神经酰胺酶抑制剂的发现:合成与结构-活性关系(SAR)
    摘要:
    酸性神经酰胺酶(AC)是一种胞内半胱氨酸酰胺酶,可催化脂质信使神经酰胺的水解。通过调节细胞中的神经酰胺水平,AC可能有助于调节癌细胞的增殖和衰老以及对癌症治疗的反应。我们最近确定了抗肿瘤剂卡莫呋(4a)是细胞内AC活性的第一个纳摩尔抑制剂(大鼠AC,IC 50 = 0.029μM)。在目前的工作中,我们在4a左右扩展了我们的初始结构-活性关系(SAR)研究通过合成和测试一系列2,4-二氧嘧啶-1-羧酰胺。我们的研究首次阐明了对AC抑制至关重要的尿嘧啶衍生物的结构特征,并促使我们确定了该酶的首个单位数纳摩尔抑制剂。本结果证实,取代的2,4-二氧嘧啶-1-羧酰胺是一类新型的有效的AC抑制剂。所选的此类化合物可代表有用的探针,以进一步表征AC的功能作用。
    DOI:
    10.1021/jm301879g
点击查看最新优质反应信息

文献信息

  • [EN] ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS<br/>[FR] INHIBITEURS DE LA CÉRAMIDASE ACIDE ET LEUR UTILISATION COMME MÉDICAMENTS
    申请人:FOND ISTITUTO ITALIANO DI TECNOLOGIA
    公开号:WO2013178545A1
    公开(公告)日:2013-12-05
    The present invention concerns, in a first aspect, compounds of Formula I as defined herein, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing such compounds. The present invention also relates to compounds of Formula I for use as acid ceramidase inhibitors, and in the treatment of cancer and other disorders in which modulation of the levels of ceramide is clinically relevant.
    本发明涉及一种第一方面的化合物,其化学式如下所定义,以及其药用盐和含有该类化合物的药物组合物。本发明还涉及化学式I的化合物作为酸酶抑制剂的用途,以及在癌症和其他需要临床上调节神经酰胺水平的疾病的治疗中的应用。
  • Synthesis,<i>In Vitro</i>Cytotoxicity and Radiosensitizing Activity of Novel 3-[(2,4-Dinitrophenylamino)Alkyl] Derivatives of 5-Fluorouracil
    作者:Ali Khalaj、Khosrou Abdi、Seyed Nasser Ostad、Mohammad Reza Khoshayand、Navid Lamei、Hasan Ali Nedaie
    DOI:10.1111/cbdd.12211
    日期:2014.2
    Previously, it was reported that 3[3‐(2,4‐dinitrophenylamino)‐propyl]‐5fluorouracil 8c unlike its components 5fluorouracil (5‐FU) 6 and 2,4‐dinitroaniline 2 in HT‐29 cells under aerobic conditions had no cytotoxicity but showed radiosensitizing activity. In this study several analogues of 8c differing in the number of linking methylene groups were prepared and tested for in vitro cytotoxicity and
    以前,有报道称HT-29细胞中的3 [3-(2,4-二硝基苯氨基)-丙基] -5-氟尿嘧啶8c与它的成分5-氟尿嘧啶(5-FU)6和2,4-二硝基苯胺2不同。有氧条件没有细胞毒性,但表现出放射增敏活性。在这项研究中,制备了几种在连接亚甲基数量上不同的8c类似物,并测试了在有氧和低氧条件下的体外细胞毒性和放射增敏活性。通过5‐FU 6与多聚甲醛和2,4-二硝基苯胺2的反应在一个锅中制备栓系化合物8a在浓盐酸存在下,通过N-(溴代烷基)-2,4-二硝基苯胺5b-f与1-(叔丁氧羰基)-5-氟尿嘧啶7反应,然后水解制备化合物8b-f的保护基团。通过3-(4,5-二甲基噻唑-2-基)-2,5-二苯基溴化四氮唑(MTT)和碘化丙啶(PI)-洋地黄皂苷测定法和敏化增强比值(SER)来测定被测化合物的细胞毒性根据在不存在和存在每种敏化剂的情况下的放射存活曲线,分别测量37%的存活率,作为放射增敏活性的量
  • [EN] BIOORTHOGONAL METHODS AND COMPOUNDS<br/>[FR] COMPOSÉS ET PROCÉDÉS BIO-ORTHOGONAUX
    申请人:UNIV EDINBURGH
    公开号:WO2014202994A1
    公开(公告)日:2014-12-24
    The invention provides a new bioorthogonal deprotection method for preparing heterocyclic compounds by bond cleavage using palladium. The methods have general application in the field of biological synthetic chemistry. Compounds, such as prodrugs, which are useful in such methods are also provided.
    该发明提供了一种新的生物正交去保护方法,通过使用钯进行键裂解来制备杂环化合物。这些方法在生物合成化学领域具有普遍应用。还提供了在这些方法中有用的化合物,如前药。
  • Design and synthesis of a β-lactamase activated 5-fluorouracil prodrug
    作者:Ryan M. Phelan、Marc Ostermeier、Craig A. Townsend
    DOI:10.1016/j.bmcl.2008.12.057
    日期:2009.2
    An efficient synthesis of a 5-fluorouracil-cephalosporin prodrug is described for use against colorectal and other cancers in antibody and gene-directed therapies. The compound shows stability in aqueous media until specifically activated by β-lactamase (βL). The kinetic parameters of the 5-fluorouracil-cephalosporin conjugate were determined in the presence of Enterobacter cloacae P99 βL (ECl βL)
    描述了一种有效合成的 5-氟尿嘧啶-头孢菌素前药,用于在抗体和基因导向疗法中对抗结直肠癌和其他癌症。该化合物在水性介质中表现出稳定性,直到被 β-内酰胺酶 (βL) 特异性激活。5-氟尿嘧啶-头孢菌素偶联物的动力学参数在阴沟肠杆菌P99 βL (ECl βL)存在下测定,显示K m  = 95.4 μM 和V max  = 3.21 μMol min -1  mg -1。该数据与已报道的相关系统相比具有优势,并且能够在体外和体内测试该前药对抗癌细胞系。
  • Conformational preferences in the β-peptide oligomers of cis-2-amino-1-fluorocyclobutane-1-carboxylic acid
    作者:Ammar Hassoun、Claire M. Grison、Régis Guillot、Thomas Boddaert、David J. Aitken
    DOI:10.1039/c4nj01929f
    日期:——

    These oligomers adopt a regular zig-zag strand-like secondary structure which does not rely on intra-residue 6-ring hydrogen bonds for stability.

    这些寡聚体采用一种规则的锯齿状链状二级结构,其稳定性不依赖于分子内6环氢键。
查看更多